Indications
Criptine Tablet is used for:
Parkinson's disease, Galactorrhoea, Hypogonadism, Infertility, acromegaly, Lactation suppression, benign breast and menstrual disorders, Amenorrhea, hyperprolactinaemia
.
Adult Dose
Adult: PO Parkinson's disease As adjunct to levodopa: 1st wk: 1-1.25 mg at night, 2nd wk: 2-2.5 mg at night; 3rd wk: 2.5 mg twice daily; 4th wk: 2.5 mg 3 times/day, then increase as needed.
Maintenance: 10-40 mg/day.
Hyperprolactinemia
Initial: 1.25-2.5 mg PO qDay
May increase by 2.5 mg/day q2-7Days
Usual therapeutic dosage 5-7.5 mg/day, ranges from 2.5-15 mg/day
Up to 30 mg/day has been used in some patients with amenorrhea &/or galactorrhea
Acromegaly (Parlodel)
1.25-2.5 mg PO qHS for 3 days
May increase by 1.25-2.5 mg/day at q3-7Days
Not to exceed 100 mg/day
Adjunct to surgery and radiotherapy in patients w/ acromegaly Initial: 2.5 mg twice daily, increase slowly, up to 5 mg 6 hrly if needed. Lactation suppression 2.5 mg/day for 2-3 days, up to 2.5 mg twice daily for 14 days.
Prevention of puerperal lactation 2.5 mg on the day of delivery, then 2.5 mg twice daily for 14 days. Cyclical benign breast and menstrual disorders 2.5 mg twice daily.
Hepatic Impairment: Dose adjustment may be necessary; there are no guidelines
Child Dose
Hyperprolactinemia
11-15 years: 1.25-2.5 mg PO qDay (initially)
Maintenance: 2.5-10 mg/day
Renal Dose
Administration
Should be taken with food.
Contra Indications
Breast carcinoma, hypersensitivity to ergot alkaloids, uncontrolled hypertension, severe ischaemic heart disease. Pregnancy and lactation.
Precautions
Increased risk of conception, patients with peptic ulcer, diabetes, diabetic retinopathy, impaired hepatic or renal function, pleuropulmonary signs and symptoms, history of psychosis, CV disease, dementia or concurrent antihypertensive therapy, ability to drive vehicles or operating machinery may be impaired.
Lactation: should not be used during lactation
Pregnancy-Lactation
Pregnancy
Safety of Bromocriptine treatment during pregnancy to the mother and fetus has not been established
If pregnancy occurs during Bromocriptine administration, careful observation of these patients is mandatory
Prolactin-secreting adenomas may expand and compression of optic/other cranial nerves may occur, emergency pituitary surgery becoming necessary; in most cases, the compression resolves following delivery
Reinitiation of Bromocriptine treatment has been reported to produce improvement in the visual fields of patients in whom nerve compression has occurred during pregnancy
In patients being treated for hyperprolactinemia, Bromocriptine should be withdrawn when pregnancy is diagnosed
Acromegaly, prolactinoma, or Parkinson disease
Patients who subsequently become pregnant, determine whether continuing therapy is medically necessary or can discontinues
If it is continued, discontinue therapy in those who may experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of Bromocriptine is considered to be medically contraindicated
Lactation
Avoid use during lactation in postpartum women
Interactions
Bioavailability increased if given along with erythromycin. Alcohol reduces tolerance to bromocriptine and vice-versa. Effects of antihypertensives may be potentiated. Avoid concurrent psychotropics.
Side Effects
Side effects of Bromocriptine :
>10%
Nausea (49%), Hypotension (30%), Headache (19%), Dizziness (17%)
1-10%
Abdominal cramps, Anorexia, Constipation, Dyspepsia, Dysphagia, Epigastric pain, GI hemorrhage, Vomiting, Drowsiness, Fatigue, Faintness, Hallucinations Visual, Insomnia, Lightheadedness, Nighmares, Paranoia, Psychosis, Seizure, Vertigo, Arrhythmias, Bradycardia, Hypertension, MI, Mottled skin, Orthostasis, Vasospasm, Palpitations, Pericardial effusions, Raynaud's syndrome exacertabtion, Syncope, Blepharospasm, BUN increased, Burning discomfort of the eye, Diplopia, Facial pallor, Leg cramps, Nasal congestion, Rash, Urticaria
Mode of Action
Bromocriptine is a dopamine D2 and D3-agonist which works by activating postsynaptic dopamine receptors in the tuberoinfundibular and nigrostriatal pathways. It also inhibits the secretion of prolactin from the anterior pituitary and is used in the treatment of prolactinoma and in endocrinological disorders.
Note
Criptine 2.5mg Tablet generic name is Bromocriptine. Criptine 2.5mg Tablet is manufactured by Renata LimitedCriptine is availble in all over Bangladesh.
Mes BD drug index information on Criptine Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.